Thus, studies have shown that the loss‐of‐function alterations of PARP1 led to a 100‐fold higher olaparib resistance than its wild‐type counterpart, and elevating the PARP1 expression may make tumours more sensitive to PARP inhibitors.39 The gene discussed is PARP1; the disease is neoplasm.